Drugs / autologous hematopoietic stem cells
last change Mar 2024 re-read 2 minutes ago

autologous hematopoietic stem cells

also known as aHSCs

Cell therapy

Developed for
acute lymphoblastic leukemia · classic stiff person syndrome · diffuse large B-cell lymphoma · large B-cell lymphoma · mantle cell lymphoma · plasma cell myeloma · sarcoidosis · glioblastoma
+1 more · metastatic neoplasm
Investigated by
Northwestern University · Joshua Sasine, MD, PhD

Trials 3 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05887167 Mar 2024 → Dec 2026 expected acute lymphoblastic leukemia, diffuse large B-cell lymphoma, large B-cell lymphoma, mantle cell lymphoma +1 Joshua Sasine, MD, PhD Recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02282514 Oct 2014 → Aug 2019 classic stiff person syndrome Northwestern University Terminated No outcome recorded
Phase 1/2 NCT00282438 Dec 2003 → Aug 2015 sarcoidosis Northwestern University Terminated No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT01759810 Comparator Dec 2012 → Dec 2018 glioblastoma NeuroVita Clinic Unknown No outcome recorded
Phase 2/3 NCT01782274 Comparator Dec 2012 → Dec 2018 metastatic neoplasm NeuroVita Clinic Unknown No outcome recorded
Phase 2/3 NCT01782287 Comparator Dec 2012 → Dec 2018 metastatic neoplasm NeuroVita Clinic Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as autologous hematopoietic stem cells Autologous hematopoietic stem cells will be injected after conditioning” NCT00282438
5

NCT01782287

NCT02282514

NCT01759810

NCT05887167

NCT01782274

Known as aHSCs “Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.” NCT05887167
Action Restore “The purpose of the stem cell infusion is to evaluate whether this treatment will produce a normal immune system that will no longer attack the body.” NCT00282438
Modality Cell therapy “Autologous hematopoietic stem cells will be injected after conditioning” NCT00282438
Route Other “Autologous hematopoietic stem cells will be injected after conditioning” NCT00282438